Resverlogix (Canada)

Recent papers from Resverlogix (Canada)

1. RVX-208Journal of the American College of Cardiology · 2010
2. BET inhibitor apabetalone suppresses the fibrotic activation of cardiac fibroblasts associated with heart dysfunctionBiomedicine & Pharmacotherapy · 2026
3. Apabetalone Drives a Metabolic Shift Towards Ketogenesis and Reduces Liver Steatosis in Diet-Induced Obesity MiceBiomedicines · 2026
4. Comparative efficacy of natural zeolite and gypsum amendments on litter quality, ammonia emissions and production performance of Japanese quailsBritish Poultry Science · 2026
5. A Mobile-Web Platform for Private Security Workforce Onboarding, Job Allocation, Attendance Verification, and Compliance Management2026
6. Terminal planning considerations for current and future trends in baggage handlingJournal of airport management · 2025
7. The High Sensitivity of the Multi-Cancer Detection Test ONCOVERYX-F Offers a Promising Platform for Ovarian Cancer ScreeningInternational Journal of Women s Health · 2024
8. Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle CellsBiomedicines · 2023
9. Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal ImpairmentBiomedicines · 2023
10. Consensus Recommendations of the Asia Pacific Cardiometabolic Consortium on Secondary Prevention Strategies in Myocardial Infarction: Recommendations on Pharmacotherapy, Lifestyle Modification and Cardiac RehabilitationJournal of Asian Pacific Society of Cardiology · 2023
11. Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver diseaseAmerican Journal of Preventive Cardiology · 2022
12. Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulatorsBiomedicine & Pharmacotherapy · 2022
13. Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapyPharmacology Research & Perspectives · 2022
14. Insulin mimetic effect of D‐allulose on apolipoprotein A‐I geneJournal of Food Biochemistry · 2022
15. Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled TrialJournal of Alzheimer s Disease · 2021
16. Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trialCardiovascular Diabetology · 2021
17. Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In VitroBiomedicines · 2021
18. Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE studyCardiovascular Diabetology · 2021
19. A Machine Learning Approach for Collusion Detection in Electricity Markets Based on Nash Equilibrium TheoryJournal of Modern Power Systems and Clean Energy · 2021
20. BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetesClinical Epigenetics · 2020